Zydus Lifesciences Announces Successful Clinical Development of Pembrolizumab Biosimilar FYB206, Marking a Milestone Toward USFDA Filing

Zydus Lifesciences, an innovation-led life-sciences company, has announced the successful clinical development of its Pembrolizumab biosimilar, FYB206. The pivotal Dahlia pharmacokinetic study has demonstrated pharmacokinetic equivalence with the oncology blockbuster drug Keytruda®. Zydus has in-licensed FYB206 exclusively from Formycon AG for the U.S. and Canadian markets. The positive clinical data marks a key milestone in the collaboration between Zydus and Formycon, reflecting their shared commitment to expand access to affordable, life-saving oncology treatments. Formycon is now focusing on completing all development activities to finalize the documents for regulatory approval, with the aim of making FYB206 available as soon as possible after the exclusivity of the reference drug expires.